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ABSTRACT  
An increased production of vasoconstrictive prostanoids, such as thromboxane 
A2 (TXA2), contributes to endothelial dysfunction and increased hepatic vascular 
tone in cirrhosis. TXA2 induces vasoconstriction via activation of the 
Thromboxane-A2/prostaglandin-endoperoxide (TP) receptor. This study 
investigates whether Terutroban, a specific TP receptor blocker, decreases 
hepatic vascular tone and portal pressure in rats with cirrhosis due to carbon 
tetrachloride (CCl4) or bile duct ligation (BDL). Hepatic and systemic 
hemodynamics, endothelial dysfunction, liver fibrosis, hepatic Rho-kinase 
activity (a marker of hepatic stellate cell contraction), and the eNOS signaling 
pathway were measured in CCl4 and BDL cirrhotic rats treated with Terutroban 
(30 mg/kg/day) or its vehicle for two weeks. Terutroban reduced portal pressure 
in both models without producing significant changes in portal blood flow, 
suggesting a reduction in hepatic vascular resistance. Terutroban did not 
significantly change arterial pressure in CCl4-cirrhotic rats but decreased it 
significantly in BDL-cirrhotic rats. In livers from CCl4 and BDL-cirrhotic 
Terutroban-treated rats, endothelial dysfunction was improved and Rho-kinase 
activity was significantly reduced. In CCl4-cirrhotic rats, Terutroban reduced liver 
fibrosis and decreased α-SMA, collagen-I and TGF-β mRNA expression without 
significant changes in eNOS pathway. In contrast, no change in liver fibrosis 
was observed in BDL-cirrhotic rats but an increase in the eNOS pathway. 
Conclusion: Our data indicate that TP-receptor blockade with Terutroban 
decreases portal pressure in cirrhosis. This effect is due to decreased hepatic 
resistance, which in CCl4-cirrhotic rats was linked to decreased hepatic fibrosis, 
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but not in BDL rats, in which the main mediator appeared to be an enhanced 
eNOS-dependent vasodilatation, which was not liver selective, as it was 
associated with decreased arterial pressure. The potential use of Terutroban for 
portal hypertension requires further investigation. 
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INTRODUCTION 
In cirrhotic livers, increased resistance to portal blood flow resulting from 
architectural alterations of the liver parenchyma as well as from increased 
hepatic vascular tone is the primary factor in the pathophysiology of portal 
hypertension (1, 2). Increased hepatic vascular tone is partly due to an 
increased production of cyclooxygenase-1 (COX-1)-derived vasoconstrictive 
prostanoids, such as thromboxane (TXA2) (3, 4) together with an insufficient 
intrahepatic availability of the vasodilator nitric oxide (NO) (5, 6). 
We have previously demonstrated that, in isolated perfused cirrhotic livers, the 
blockade of the TXA2/PGH2 (TP) receptor with SQ29548 corrected the 
hyperresponse to methoxamine (3) and improved endothelial dysfunction (4) of 
the hepatic vascular bed.  Moreover, sinusoidal endothelial cells (SEC) isolated 
from cirrhotic rats overexpress COX-1 (7) and thromboxane synthase (TXAS) 
(8), which represent an important source of vasoconstrictor prostanoids, such 
as TXA2 (9). Importantly, COX inhibition not only reduces the exaggerated TXA2 
production of cirrhotic SEC but also restores, at least in part, its decreased NO 
bioavailability (8).  
TP receptor ligands include TXA2, PGH2 and isoprostanes (10, 11). TXA2 acts 
through its G-protein-coupled receptor leading to vasoconstriction by activating 
the RhoA/Rho-kinase pathway, and by increasing calcium levels in hepatic 
stellate cells (HSC) (12). Terutroban is an orally active, specific antagonist of 
the TP-receptor (13) that improves endothelial-dependent vasodilation (14), 
reduces inflammation (15), attenuates oxidative stress and exerts antifibrotic 
effects (16, 17) in different vascular disorders. In addition, Terutroban has been 
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shown to reduce RhoA/Rho-kinase-dependent signaling and restore NO 
bioavailability in endotelial cells (18, 19).  
The current study aimed at evaluating the long-term effects of the in vivo 
blockade of TP receptor with Terutroban in two experimental rat models of 
cirrhosis, carbon tetrachloride (CCl4) and bile duct ligation (BDL). 
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MATERIALS AND METHODS 
Induction of cirrhosis by carbon tetrachloride (CCl4) 
Male Wistar rats weighing 50 to 75g underwent inhalation exposure to CCl4 
three times a week as previously described (20). A high yield of micronodular 
cirrhosis was obtained after approximately 12 to 15 weeks of CCl4 inhalation. 
When the cirrhotic rats developed ascites, administration of CCl4 was stopped.  
 
Induction of cirrhosis by bile duct ligation (BDL)  
Secondary biliary cirrhosis was induced in male Sprague-Dawley rats (200 to 
225 g) by BDL as previously described (21).  
 
Terutroban treatment 
Cirrhotic rats were randomized to receive Terutroban (30mg/Kg; n= 13 in CCl4; 
n=14 in BDL; kindly supplied by Servier, Courbevoie Cedex, France) or its 
vehicle (1% hydroxyethylcellulose; n=8 in CCl4; n=16 in BDL; Sigma-Aldrich, 
Tres Cantos, Madrid, Spain), administered orally by gavage, once a day, for 2 
weeks. Treatment started one week after development of ascitis and stopping 
CCl4 administration in a setting of advanced cirrhosis or after two weeks of BDL, 
in a precirrhotic stage. Experiments were performed 1 hour after the last dose of 
Terutroban or vehicle. Treatments were prepared by a third person and 
experimental studies were realized blindly. The code was kept sealed until the 
final analysis of the results. The dose of Terutroban used has been previously 
shown to have antivasoconstricting and antiatherosclerotic properties (16, 22, 
23). 
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The animals were kept in environmentally controlled animal facilities at the 
Institut d’Investigacions Biomèdiques August Pi i Sunyer. All procedures were 
approved by the Laboratory Animal Care and Use Committee of the University 
of Barcelona and were conducted in accordance with European Community 
guidelines for the protection of animals used for experimental and other 
scientific purposes (EEC Directive 86/609). 
 
In vivo hemodynamic studies 
Cirrhotic rats were anesthetised with intraperitoneal ketamine hydrochloride 
(100 mg/Kg; Merial Laboratories, Barcelona, Spain) plus midazolam (5 mg/kg 
intraperitoneally; Laboratorios Reig Jofré, Barcelona, Spain). The femoral artery 
and the ileocolic vein were cannulated with PE-50 catheters to measure mean 
arterial pressure (MAP; mmHg) and portal pressure (PP; mmHg) respectively. 
Perivascular ultrasonic transit-time flow probes connected to a flow meter 
(Transonic Systems Inc., Ithaca, NY, USA) were placed around the portal vein, 
as close as possible to the liver to measure portal blood flow perfusing the liver 
(PBF; mL/min/g liver) and around the superior mesenteric artery, in BDL 
cirrhotic rats, to measure superior mesenteric artery blood flow (SMABF, 
mL/minute/100g body weight). Hepatic vascular resistance (HVR, 
mmHg/mL/min/g liver) was calculated as: PP/PBF and superior mesenteric 
artery resistance (SMAR, mmHg/mL/min/100g body weight) was calculated as 
(MAP-PP)/SMABF. Blood pressures and flows were registered on a 
multichannel computer-based recorder (PowerLab; AD Instruments, Colorado 
Springs, CO). The temperature of the animals was maintained at 37± 0.5°C. 
Hemodynamic data were collected after a 20 min stabilization period.  
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Efficacy of TP receptor blockade 
To determine if Terutroban correctly blocked the TP receptor, in a subgroup of 
CCl4 and BDL cirrhotic rats (n=3) treated with Terutroban (30mg/kg) or vehicle 
for 2 weeks, measurements of MAP and PP were performed before and after 
the intravenous infusion of 10 µg/Kg U46619 (24). U46619 (9,11-dideoxy-
9α,11α-methanoepoxy-prosta-5Z,13E-dien-1-oic acid; Cayman Chem. Co.) is a 
synthetic TXA2 analogue that specifically activates the TP-receptor. 
 
Evaluation of endothelial function 
An additional group of cirrhotic rats were randomized to receive Terutroban (30 
mg/Kg; n= 8 in CCl4; n =8 in BDL) or vehicle (n= 9 in CCl4; n =9 in BDL) for 
three days. Rats were anesthetized and livers were quickly isolated and 
perfused by a flow-controlled perfusion system as previously described (25). 
The perfused rat liver preparation was allowed to stabilize for 20 min before 
vasoactive substances were added. The intrahepatic microcirculation was 
preconstricted by adding the α1-adrenergic agonist methoxamine (Mtx; 10-4 
mol/L; Sigma) to the reservoir. After 5 min, concentration–response curves to 
cumulative doses of acetylcholine (Ach; 10-7, 10-6, and 10-5 mol/L; Sigma) were 
evaluated. Responses to Ach were calculated as per cent change in portal 
perfusion pressure (26). The gross appearance of the liver, stable perfusion 
pressure, bile production over 0.4 ul/min/g of liver and a stable buffer pH (7.4 ± 
0.1) were monitored during this period. If any viability criteria were not satisfied, 
the experiment was discarded. 
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Biochemical analysis 
At the end of the in vivo hemodynamic study, serum samples from cirrhotic rats 
were collected by cardiac puncture to subsequently evaluate alanine 
aminotransferase (ALT), aspartate aminoransferase (AST), bilirubin and 
albumin, all by standard protocols. 
 
Assesment of Rho-kinase activity 
Hepatic samples were obtained as previously described (27). Rho-kinase 
activity was assessed by the phosphorylation of the endogenous Rho-kinase 
substrate, moesin at Thr558 normalized to the level of total moesin expression. 
Moesin-phosphorylation and moesin total expression were assessed by 
Western Blot using a goat antiphosphorylated moesin at Thr558 antibody (1:200; 
Santa Cruz Biotechnology, California, USA) and a mouse antibody recognizing 
moesin (1:200; Santa Cruz Biotechnology) overnight at 4°C followed by 
incubation with their associated horseradish peroxidase–conjugated secondary 
antibody (1:10000, 1 hour, room temperature, Stressgen Victoria, British 
Columbia, Canada). After stripping, blots were assayed for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression as standardization of sample 
loading.  
 
Evaluation of NO pathway 
Western blot analysis of eNOS-phosphorylation and eNOS total protein 
expression 
eNOS-phosphorylation (eNOS-P) and eNOS total expression were assessed in 
hepatic homogenates using a rabbit antiphosphorylated eNOS at Ser1176 
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(1:1000; Cell Signaling Technology Beverly, MA) and a mouse antibody 
recognizing eNOS (1:1000; BD Transduction Laboratories, Lexington, KY). 
Quantitative densitometric values of proteins were normalized to GAPDH. 
cGMP levels 
Measurements of cGMP, a secondary marker of NO bioavailability, were 
performed in rat liver homogenates treated with Terutroban or vehicle by 
enzyme immunoassay (Cayman Chem. Co. Tallin, Estonia) as previously 
described (28). 
 
Evaluation of hepatic fibrosis 
Quantification of hepatic fibrosis 
Livers from cirrhotic rats were fixed in 10% formalin, embedded in paraffin, 
sectioned and stained with 0.1% Sirius red, photographed, and analyzed using 
a microscope equipped with a digital camera. Eight fields from each slide were 
randomly selected, and the red-stained area per total area was measured using 
AxioVision software {Rodriguez-Vilarrupla, 2012 4577 /id}. Values are 
expressed as the mean of 8 fields taken from Vehicle- (n=9) and Terutroban- 
(n=11) CCl4-cirrhotic rats or n=10 animals per group in the BDL model. 
Protein expression of α-smooth muscle actin (α-SMA) 
Hepatic protein expression of α-SMA was determined by Western blot in 
hepatic samples using a mouse antibody against α-SMA (1:1000, Sigma-
Aldrich). 
Collagen I and TGF-β gene expression 
Hepatic mRNA expression of Collagen I and TGF-β was analyzed by real-time 
PCR using predesigned gene expression assays obtained from Applied 
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Biosystems (AB, Foster City, CA) according to the manufacturer’s protocol and 
reported relative to endogenous control GAPDH. All PCR reactions were 
performed in duplicate and using nuclease-free water as no template control.  
 
Analysis of TP receptor expression in HSC 
To directly study the expression of TP receptor, hepatic stellate cells (HSC) 
were isolated from control, CCl4-, sham operated and BDL- rats as previously 
described (29). In the CCl4 model, HSC were isolated one week after 
development of ascitis and in the BDL model two weeks after surgery (when 
Terutroban treatment was initiated in the in vivo studies). TP receptor protein 
expression was determined by Western Blot in hepatic samples using a mouse 
antibody against TP receptor (1:1000; Cayman Chem Co.). 
 
Statistical analysis 
Statistical analysis was performed with the SPSS 18.0 for Windows statistical 
package (IBM Corp., Armonk, NY). All results are expressed as mean ± SEM. 
Comparisons between groups were performed with the Student t test for 
unpaired data or with Mann-Whitney test when assumptions of normality could 
not be verified. Differences were considered significant at a P value < 0.05. 
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RESULTS 
Efficacy of TP receptor blockade in CCl4 and BDL cirrhotic rats 
As expected, infusion of U46619 produced a significant increase in MAP (23 ± 
13%) and PP (11 ± 5%) in CCl4-cirrhotic rats treated with vehicle (Fig 1A and 
1B, black bars). By contrast, in CCl4-cirrhotic rats treated with Terutroban, the 
increase of MAP (3 ± 5%) and PP (2 ± 3%) in response to TP agonist was 
markedly attenuated, indicating an effective blockade of the TP-receptor (Fig 1A 
and 1B, white bars). Terutroban produced a similar blockade of the TP-receptor 
in BDL-cirrhotic rats, as shown by the attenuation of the increase in MAP (5 ± 
3% vs 18 ± 8% in vehicle) and in PP (3 ± 3% vs 12 ± 3% in vehicle) caused by 
U46619 (Fig 1D, 1E). 
 
TP receptor protein expression in CCl4 and BDL cirrhotic rats 
TP receptor expression was determined in HSC from control, CCl4- (Fig 1C) 
and BDL- cirrhotic rats (Fig.1F). Both cirrhotic models exhibited a significantly 
higher TP receptor expression compared to control rats. 
 
Effects of chronic treatment with Terutroban in CCl4-cirrhotic rats  
TP receptor blockade lowers portal pressure in CCl4-cirrhotic rats  
PP was significantly lower in CCl4-cirrhotic rats treated with Terutroban (11.9 ± 
2.8 mmHg) as compared with vehicle-treated rats (14.5 ± 1.4 mmHg) (mean 
difference -17.9%; p=0.035). This reduction was not associated with a 
significant change in PBF reflecting a fall in HVR (7.9 ± 2.6 vs 10.3 ± 2.9 
mmHg/ml/min/g in vehicle-treated rats) (mean decrease 25%; p=0.047). MAP 
was not significantly reduced by Terutroban (Fig 2). 
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TP receptor blockade attenuates Rho-kinase activity in CCl4-cirrhotic rats 
To further explore the intrahepatic molecular mechanisms behind TP receptor 
blockade, we evaluated moesin phosphorylation in hepatic samples, a marker 
of Rho kinase activity. TP receptor blockade with Terutroban reduced hepatic 
moesin phosphorylation indicating a reduction in Rho-kinase activity (Fig 3B).  
Since RhoA/Rho-kinase may modulate eNOS activity, we characterized eNOS 
expression and phosphorylation. However, Terutroban administration did not 
modify eNOS phosphorylation at Ser1176 (Fig 3C), total eNOS expression (Fig 
3D) or hepatic cGMP levels (18.3 ± 2.9 pmol/ml vs 19.2 ± 3.4 pmol/ml in 
vehicle-treated rats) (Fig 3E).     
 
TP receptor blockade attenuates hepatic fibrosis in CCl4-cirrhotic rats 
As expected, CCl4-cirrhotic rats exhibited a marked distortion of the normal liver 
architecture, as identified by staining of liver sections with Sirius Red. 
Terutroban treatment produced a significant reduction in hepatic fibrosis, 
measured by the percentage of fibrosis area on Sirius Red stained liver sections 
(13.7% ± 4 vs 20.8% ± 3 in vehicle-treated rats) (Fig 4A). This was associated 
with a significant reduction in collagen I mRNA expression (Fig 4B), a marked 
decrease in α-SMA protein expression, a surrogate marker of HSC activation 
(Fig 4C), and decreased TGF-β mRNA levels (Fig 4D). 
 
Effects of TP receptor blockade on liver function in CCl4-cirrhotic rats 
There were no significant differences in transaminases or bilirubin between 
CCl4-cirrhotic rats treated with vehicle or Terutroban. However, albumin levels 
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were significantly increased in Terutroban-treated rats. Liver, spleen and body 
weight were not different between groups (Table 1A).  
 
TP receptor blockade improves endothelial dysfunction in CCl4-cirrhotic 
rats 
Improved vasorelaxation in response to Ach was observed in three days 
Terutroban-treated rats in comparison to cirrhotic rats treated with vehicle, that 
exhibited the expected impaired vasodilatory response to Ach (endothelial 
dysfunction) (Fig 3A). After NO synthase inhibition, Terutroban also improved 
the vasodilatory response to Ach (Ach 10-7 M: -4.3 ± 0.3%; 10-6 M: -8.0 ± 1.5%; 
10-5M:  -14.3±2.4). 
 
Effects of chronic treatment with Terutroban in BDL-cirrhotic rats  
TP receptor blockade lowers portal pressure in BDL-cirrhotic rats  
BDL cirrhotic rats treated with Terutroban also had a significantly lower PP than 
those treated with vehicle (15.2 ± 1.9 vs 17.3 ± 2 mmHg; p=0.007; mean 
difference -12.1%). Reduction in PP was observed without significant changes 
in PBF supporting a reduction in HVR (17.8 ± 5.2 vs 22.8 ± 3.8 mmHg/ml/min/g; 
p=0.038; mean decrease 22%). However, BDL rats treated with Terutroban 
exhibited a significantly lower MAP (70 ± 8 mmHg vs 91 ± 16 mmHg; p<0.05) 
than those receiving vehicle. As SMABF was similar in both groups, Terutroban 
produced a significant reduction in splanchnic arteriolar resistance (Fig 5). 
 
TP receptor blockade attenuates Rho-kinase activity and improves NO 
bioavailability in BDL-cirrhotic rats 
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Moesin phosphorylation was significantly decreased in livers from Terutroban-
treated BDL rats (Fig 6B). Contrary to CCl4-cirrhotic rats, livers from BDL rats 
treated with Terutroban exhibited an enhanced eNOS phosphorylation at 
Ser1176 (Fig 6C) and increased total eNOS expression (Fig 6D), together with 
increased hepatic cGMP levels (7.2 ± 2.7 pmol/ml vs 4.1 ± 2.5 pmol/ml in 
vehicle-treated rats; p <0.05) (Fig 6E). 
 
TP receptor blockade does not attenuate hepatic fibrosis in BDL-cirrhotic rats 
Contrary to CCl4-cirrhotic rats, Terutroban administration to BDL rats did not 
reduce liver fibrosis as evaluated by the percentage of Sirius staining (36.9% ± 
3.7 vs 34.7% ± 7.5 in vehicle) (Fig 7A), and did not significantly change α-SMA 
protein expression (Fig 7C), Type I collagen (Fig 7B) or TGF-β mRNA levels 
(Fig 7D). 
 
Effects of TP receptor blockade on liver function in BDL-cirrhotic rats 
There were no significant differences in transaminases, bilirubin or albumin 
between BDL cirrhotic rats treated with vehicle or Terutroban. Liver, spleen and 
body weight were not different between groups (Table 1B).  
 
TP receptor blockade improves endothelial dysfunction in BDL-cirrhotic 
rats 
Livers from cirrhotic rats treated with vehicle exhibited an impaired vasodilatory 
response to Ach. Terutroban treatment significantly improved vasorelaxation in 
response to Ach (Fig 6A). 
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DISCUSSION 
An increase in the hepatic production of the vasoconstrictor prostanoid TXA2 
has been shown to increase hepatic resistance in cirrhotic livers, contributing to 
increased portal pressure (3, 20, 30-32). Up to now, in vivo efforts to reduce this 
increased hepatic resistance by reducing TXA2 levels have been based on 
treatments with non-selective COX inhibitors (32, 33). However, the strategy to 
block TXA2 production by non-selective COX inhibition is not acceptable in 
cirrhosis due to its demonstrated deleterious effects on sodium and water 
retention and renal function (34, 35). There are no previous reports of the 
effects of TP-receptor blockade in vivo in cirrhotic animals. We hereby report 
the effects of Terutroban, a specific TP-receptor blocker, in cirrhotic rats. 
Terutroban has been extensively used in clinical trials in vascular diseases and 
proved to be safe (14, 36, 37). 
Our study demonstrates that in vivo chronic TP-receptor blockade with 
Terutroban produced a similar reduction in portal pressure in two different 
models, CCl4 and BDL. The decrease in portal pressure was not associated 
with changes in portal blood flow, suggesting a reduction in hepatic vascular 
resistance. This beneficial effect of Terutroban on hepatic resistance should be 
attributed, in part, to the blockade of the vasoconstrictor effect of TXA2 (3, 32). 
Indeed, the blunted increase in portal pressure after the infusion of the TXA2 
agonist U46619 in Terutroban-treated rats suggests an adequate TP-receptor 
blockade and inhibition of TXA2-derived vasoconstriction of HSC and/or 
vascular smooth muscle cells in the hepatic vasculature. We also characterized 
the effects of Terutroban on Rho-kinase activity. Rho-kinase, which is activated 
among other factors by the TP-receptor, is a well known mechanism of HSC 
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contraction (18, 38, 39) and it has been recently shown that its inhibition 
reduces hepatic vascular resistance (40, 41). Our results showing that 
Terutroban reduces hepatic Rho-kinase activity in both experimental models 
suggest that this may be an additional mechanism by which Terutroban 
decreases hepatic vascular resistance. 
However, other effects of Terutroban were different according to the cirrhotic rat 
model. In CCl4-cirrhotic rats, Terutroban ameliorated the architectural 
abnormalities of the liver, as shown by the reduction in liver fibrosis area on 
Sirius Red staining. This was associated with a decrease in collagen I mRNA 
expression, suggesting a reduced collagen synthesis as a consequence of TP-
receptor blockade, as it was not observed in vehicle-treated rats. This effect 
was associated, and probably linked, to a reduction of HSC activation, as 
suggested by the decreased α−SMA protein expression. It has been suggested 
that isoprostanes, a natural ligand for TP receptor, have been identified in HSC 
and mediate HSC proliferation and collagen production (11). Furthermore, 
Terutroban significantly reduced TGF-β, which is one of the main fibrogenic 
cytokines that stimulates extracellular matrix deposition (42). These findings are 
in agreement with previous studies in an animal model of severe arterial 
hypertension showing that Terutroban was able to prevent fibrosis in the aorta 
by reducing TGF-β gene expression (16). Thus, in CCl4-cirrhotic rats, both 
reduction in fibrosis and decreased hepatic vascular tone contribute to decrease 
the hepatic vascular resistance. Remarkably, the beneficial effects of 
Terutroban on fibrosis were not observed in the BDL model. Although we do not 
have an explanation for this, we may speculate that this differential effect on 
fibrosis may be due to the fact that the BDL model is characterized by a very 
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rapid and progressive fibrosis while CCl4 represents a model with much slower 
fibrosis, susceptible of regression once CCl4 inhalation is interrupted.  
Another differential effect of Terutroban between models was that observed on 
the NO signaling pathway. In BDL rats, Terutroban promoted a significant 
increase of both eNOS protein expression, of its biologically active 
phosphorylated form, and the NO second messenger, cGMP, suggesting that in 
BDL rats, an increase in NO bioavailability may also play a role reducing 
hepatic vascular resistance. By contrast, TP-receptor blockade in CCl4-cirrhotic 
rats did not produce significant changes in any of these parameters. At present, 
we have not a clear explanation for such differential effect of Terutroban. It is 
remarkable that although Terutroban did not change MAP in CCl4-cirrhotic rats, 
this was not the case in BDL rats where a marked reduction was observed. It is 
possible that in the more severe ill rats with BDL cirrhosis, blocking the TXA2 
vasoconstrictive systemic pathway together with an increase in NO 
bioavailability probably also at the systemic level, may be responsible for such 
effect decreasing MAP. 
It is important to emphasize that Terutroban reduces portal pressure in two 
different experimental settings of chronic liver disease. In the BDL model, 
Terutroban was administered after 2 weeks of bile duct ligation when cirrhosis 
and the portal hypertension syndrome is not fully established and there is still 
an ongoing active injury. In this situation, although we can not discard that 
longer periods of treatment may act on fibrosis, the main effect of Terutroban 
was over the dynamic component of resistance. By contrast, in the CCl4 model, 
Terutroban was administered once the injury (CCl4 inhalation) has been 
stopped in a setting of potential fibrosis reversal. Here, in addition to improving 
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the dynamic component of the hepatic resistance, Terutroban also facilitates 
fibrosis regression.   
In conclusion, our data show that TP-receptor blockade with Terutroban 
significantly reduces portal pressure in cirrhotic rats by decreasing hepatic 
vascular resistance (with a similar and comparable order of magnitude in both 
cirrhotic models), suggesting that Terutroban may represent a useful agent in 
the treatment of portal hypertension in cirrhosis. However, in further 
translational steps of the investigation a special care must be taken in possible 
effects reducing MAP. 
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FIGURE LEGENDS: 
Fig 1. Efficacy of Thromboxane/prostaglandin endoperoxide (TP) receptor 
blockade in CCl4- and BDL-cirrhotic rats. 
Effects of the infusion of the thromboxane (TXA2) agonist, U46619, in mean 
arterial pressure (MAP) and portal pressure (PP) in CCl4- (Fig 1A, 1B) and BDL-
cirrhotic rats (Fig 1D, 1E) treated with Vehicle or Terutroban. Measurements 
were obtained at baseline and after an intravenous infusion of the TXA2 agonist. 
Data as presented as % of increment above baseline and are mean ± SEM 
(n=3 per group).  *p<0.05 vs. Vehicle. 
Representative Western Blot of TP expression in isolated hepatic stellate cells 
(HSC) from sham, CCl4- and BDL-cirrhotic rats. Densitometry quantification in 
arbitrary units (AU) showed a significant increase in TP receptor expression in 
HSC from CCl4 (Fig 1C) and BDL (Fig 1F) compared to HSC from sham rats. 
Data are presented as mean ± SEM (n=4 per group). * p<0.05 vs sham. 
 
Fig 2. Effects of Terutroban on hepatic and systemic hemodynamics in 
CCl4-cirrhotic rats. 
Effects of Terutroban (30mg/Kg/day for 2 weeks) on portal pressure (PP), portal 
blood flow (PBF), hepatic vascular resistance (HVR) and mean arterial pressure 
(MAP) in CCl4-cirrhotic rats. Data are presented as mean ± SEM (Vehicle, n=8; 
Terutroban, n=13). *p<0.05 vs. Vehicle.  
 
Fig 3. Effects of Terutroban on endothelial function, Rho-kinase and eNOS 
pathways in CCl4-cirrhotic rats. 
Page 21 of 37
Hepatology
Hepatology
 22
(A) Endothelium-dependent vasorelaxation to Acetylcholine (Ach) in isolated 
and perfused livers of CCl4-cirrhotic rats treated with Vehicle or Terutroban. 
Terutroban treatment significantly improved the impaired vasodilatory response 
to Ach in CCl4-cirrhotic rat livers. Data are presented as mean ± SEM (Vehicle, 
n=9; Terutroban, n=8) *p<0.05 vs. Vehicle. 
(B) Representative Western blot and analysis of moesin phosphorylation 
normalized to total moesin expression in CCl4-cirrhotic livers treated with 
Vehicle or Terutroban. Densitometry quantification in arbitrary units (AU) 
showed a significant decrease in moesin phosphorylation at Thr558 in 
Terutroban-treated rats.  
Representative Western blot and analysis of (C) P-eNOS and (D) eNOS in 
CCl4-cirrhotic livers treated with Vehicle or Terutroban. Densitometry 
quantification in arbitrary units (AU), normalized to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), showed no differences between both groups. Data 
are presented as mean ± SEM (n=7 per group). * p <0.05 vs Vehicle. 
(E) Intrahepatic cGMP levels in CCl4-cirrhotic rats treated with Vehicle or 
Terutroban. cGMP levels were not significantly different between groups (n=9 
per group). Data are presented as mean ± SEM.  
 
Fig 4. Effects of Terutroban on hepatic fibrosis in CCl4-cirrhotic rats. 
(A) Top: Representative histological images of livers stained with Sirius red 
from Vehicle or Terutroban treated CCl4-cirrhotic rats (original magnification 
5X). Bottom: Quantification of liver fibrosis (% quantification of Sirius Red 
staining area = Sirius Red staining area/total area*100). Terutroban treated 
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CCl4-cirrhotic rats showed a significant decrease in hepatic fibrosis. (Vehicle, 
n=9; Terutroban, n=11).  
(B) Collagen I mRNA expression levels in livers from CCl4-cirrhotic rats treated 
with Terutroban or Vehicle. Values were significantly decreased in Terutroban-
treated rats. (Vehicle, n=9; Terutroban, n=12). 
 (C) Top: Representative Western blot analysis for α-SMA in livers from Vehicle 
or Terutroban-treated CCl4 rats. Bottom: Densitometry quantification in arbitrary 
units (AU), normalized to GAPDH, showed a significant decrease in Terutroban-
treated rats. (n=7 per group).  
 (D) TGF-β mRNA expression levels in livers from CCl4-cirrhotic rats treated 
with Terutroban or Vehicle. Values showed a significant decrease in 
Terutroban-treated rats. (Vehicle, n=9; Terutroban, n=12). Data are presented 
as mean ± SEM. * p <0.05 vs Vehicle. 
 
Fig 5. Effects of Terutroban on hepatic and systemic hemodynamics in 
BDL-cirrhotic rats. 
Effects of Terutroban (30mg/Kg/day) on portal pressure (PP), portal blood flow 
(PBF), hepatic vascular resistance (HVR), mean arterial pressure (MAP), 
superior mesenteric artery blood flow (SMABF) and superior mesenteric arterial 
resistance (SMAR) in BDL-cirrhotic rats. Data are presented as mean ± SEM 
(Vehicle, n=16; Terutroban, n=14). *p<0.05 vs. Vehicle.  
 
Fig 6. Effects of Terutroban on endothelial function, Rho-kinase and eNOS 
pathways in BDL-cirrhotic rats. 
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(A) Endothelium-dependent vasorelaxation to Acetylcholine (Ach) in isolated 
and perfused livers of BDL-cirrhotic rats treated with Vehicle or Terutroban. 
Terutroban treatment significantly improved the impaired vasodilatory response 
to Ach in BDL-cirrhotic rat livers. Data are presented as mean ± SEM (Vehicle, 
n=9; Terutroban, n=8) *p<0.05 vs. Vehicle. 
(B) Representative Western blot and analysis of moesin phosphorylation 
normalized to total moesin expression, in BDL-cirrhotic livers treated with 
Vehicle or Terutroban. Densitometry quantification showed a significant 
decrease in moesin phosphorylation in Terutroban-treated rats. (n=13 per 
group).  
Representative Western blot and analysis of (C) P-eNOS and (D) eNOS in BDL 
cirrhotic livers treated with Vehicle or Terutroban. Densitometry quantification in 
arbitrary units (AU), normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), showed a significant increase in eNOS phosphorylation and eNOS 
total protein expression in Terutroban-treated rats. (n=14 per group).  
(E) Intrahepatic cGMP levels in BDL cirrhotic rats treated with Vehicle or 
Terutroban. cGMP levels were significantly increased in Terutroban treated rat 
livers. (n=13 per group). Data are presented as mean ± SEM. * p <0.05 vs 
Vehicle. 
 
Fig 7. Effects of Terutroban on hepatic fibrosis in BDL-cirrhotic rats. 
(A) Top: Representative histological images of livers stained with Sirius red 
from Vehicle or Terutroban treated BDL-cirrhotic rats (original magnification 5X). 
Bottom: Quantification of liver fibrosis (% quantification of Sirius Red staining 
area = Sirius Red staining area/total area*100). BDL cirrhotic rats treated with 
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Terutroban or vehicle showed no differences between both groups. (n=10 per 
group).  
 (B) Collagen I mRNA expression levels in livers from BDL-cirrhotic rats treated 
with Terutroban or Vehicle, showed no differences between both groups. (n=14 
per group).  
(C) Top: Representative Western blot analysis for α-SMA in livers from Vehicle 
or Terutroban-treated BDL rats. Bottom: Densitometry quantification in arbitrary 
units (AU), normalized to GAPDH, showed no differences between both groups. 
(n=14 per group). 
(D) TGF-β mRNA expression levels in livers from BDL-cirrhotic rats treated with 
Terutroban or Vehicle showed no differences between both groups. (n=14 per 
group). Data are presented as mean ± SEM.  
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Fig 1. Efficacy of Thromboxane/prostaglandin endoperoxide (TP) receptor blockade in CCl4- and BDL-
cirrhotic rats.  
Effects of the infusion of the thromboxane (TXA2) agonist, U46619, in mean arterial pressure (MAP) and 
portal pressure (PP) in CCl4- (Fig 1A, 1B) and BDL-cirrhotic rats (Fig 1D, 1E) treated with Vehicle or 
Terutroban. Measurements were obtained at baseline and after an intravenous infusion of the TXA2 agonist. 
Data as presented as % of increment above baseline and are mean ± SEM (n=3 per group).  *p<0.05 vs. 
Vehicle.  
Representative Western Blot of TP expression in isolated hepatic stellate cells (HSC) from sham, CCl4- and 
BDL-cirrhotic rats. Densitometry quantification in arbitrary units (AU) showed a significant increase in TP 
receptor expression in HSC from CCl4 (Fig 1C) and BDL (Fig 1F) compared to HSC from sham rats. Data are 
presented as mean ± SEM (n=4 per group). * p<0.05 vs sham.  
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Fig 2. Effects of Terutroban on hepatic and systemic hemodynamics in CCl4-cirrhotic rats.  
Effects of Terutroban (30mg/Kg/day for 2 weeks) on portal pressure (PP), portal blood flow (PBF), hepatic 
vascular resistance (HVR) and mean arterial pressure (MAP) in CCl4-cirrhotic rats. Data are presented as 
mean ± SEM (Vehicle, n=8; Terutroban, n=13). *p<0.05 vs. Vehicle.  
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Fig 3. Effects of Terutroban on endothelial function, Rho-kinase and eNOS pathways in CCl4-cirrhotic rats.  
(A) Endothelium-dependent vasorelaxation to Acetylcholine (Ach) in isolated and perfused livers of CCl4-
cirrhotic rats treated with Vehicle or Terutroban. Terutroban treatment significantly improved the impaired 
vasodilatory response to Ach in CCl4-cirrhotic rat livers. Data are presented as mean ± SEM (Vehicle, n=9; 
Terutroban, n=8) *p<0.05 vs. Vehicle.  
(B) Representative Western blot and analysis of moesin phosphorylation normalized to total moesin 
expression in CCl4-cirrhotic livers treated with Vehicle or Terutroban. Densitometry quantification in 
arbitrary units (AU) showed a significant decrease in moesin phosphorylation at Thr558 in Terutroban-
treated rats.  
Representative Western blot and analysis of (C) P-eNOS and (D) eNOS in CCl4-cirrhotic livers treated with 
Vehicle or Terutroban. Densitometry quantification in arbitrary units (AU), normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), showed no differences between both groups. Data are presented as 
mean ± SEM (n=7 per group). * p <0.05 vs Vehicle.  
(E) Intrahepatic cGMP levels in CCl4-cirrhotic rats treated with Vehicle or Terutroban. cGMP levels were not 
significantly different between groups (n=9 per group). Data are presented as mean ± SEM.  
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Fig 4. Effects of Terutroban on hepatic fibrosis in CCl4-cirrhotic rats.  
(A) Top: Representative histological images of livers stained with Sirius red from Vehicle or Terutroban 
treated CCl4-cirrhotic rats (original magnification 5X). Bottom: Quantification of liver fibrosis (% 
quantification of Sirius Red staining area = Sirius Red staining area/total area*100). Terutroban treated 
CCl4-cirrhotic rats showed a significant decrease in hepatic fibrosis. (Vehicle, n=9; Terutroban, n=11).  
(B) Collagen I mRNA expression levels in livers from CCl4-cirrhotic rats treated with Terutroban or Vehicle. 
Values were significantly decreased in Terutroban-treated rats. (Vehicle, n=9; Terutroban, n=12).  
(C) Top: Representative Western blot analysis for α-SMA in livers from Vehicle or Terutroban-treated CCl4 
rats. Bottom: Densitometry quantification in arbitrary units (AU), normalized to GAPDH, showed a significant 
decrease in Terutroban-treated rats. (n=7 per group).  
(D) TGF-β mRNA expression levels in livers from CCl4-cirrhotic rats treated with Terutroban or Vehicle. 
Values showed a significant decrease in Terutroban-treated rats. (Vehicle, n=9; Terutroban, n=12). Data 
are presented as mean ± SEM. * p <0.05 vs Vehicle.  
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Fig 5. Effects of Terutroban on hepatic and systemic hemodynamics in BDL-cirrhotic rats.  
Effects of Terutroban (30mg/Kg/day) on portal pressure (PP), portal blood flow (PBF), hepatic vascular 
resistance (HVR), mean arterial pressure (MAP), superior mesenteric artery blood flow (SMABF) and superior 
mesenteric arterial resistance (SMAR) in BDL-cirrhotic rats. Data are presented as mean ± SEM (Vehicle, 
n=16; Terutroban, n=14). *p<0.05 vs. Vehicle.  
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Fig 6. Effects of Terutroban on endothelial function, Rho-kinase and eNOS pathways in BDL-cirrhotic rats.  
(A) Endothelium-dependent vasorelaxation to Acetylcholine (Ach) in isolated and perfused livers of BDL-
cirrhotic rats treated with Vehicle or Terutroban. Terutroban treatment significantly improved the impaired 
vasodilatory response to Ach in BDL-cirrhotic rat livers. Data are presented as mean ± SEM (Vehicle, n=9; 
Terutroban, n=8) *p<0.05 vs. Vehicle.  
(B) Representative Western blot and analysis of moesin phosphorylation normalized to total moesin 
expression, in BDL-cirrhotic livers treated with Vehicle or Terutroban. Densitometry quantification showed a 
significant decrease in moesin phosphorylation in Terutroban-treated rats. (n=13 per group).  
Representative Western blot and analysis of (C) P-eNOS and (D) eNOS in BDL cirrhotic livers treated with 
Vehicle or Terutroban. Densitometry quantification in arbitrary units (AU), normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), showed a significant increase in eNOS phosphorylation and eNOS total 
protein expression in Terutroban-treated rats. (n=14 per group).  
(E) Intrahepatic cGMP levels in BDL cirrhotic rats treated with Vehicle or Terutroban. cGMP levels were 
significantly increased in Terutroban treated rat livers. (n=13 per group). Data are presented as mean ± 
SEM. * p <0.05 vs Vehicle.  
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Fig 7. Effects of Terutroban on hepatic fibrosis in BDL-cirrhotic rats.  
(A) Top: Representative histological images of livers stained with Sirius red from Vehicle or Terutroban 
treated BDL-cirrhotic rats (original magnification 5X). Bottom: Quantification of liver fibrosis (% 
quantification of Sirius Red staining area = Sirius Red staining area/total area*100). BDL cirrhotic rats 
treated with Terutroban or vehicle showed no differences between both groups. (n=10 per group).  
(B) Collagen I mRNA expression levels in livers from BDL-cirrhotic rats treated with Terutroban or Vehicle, 
showed no differences between both groups. (n=14 per group).  
(C) Top: Representative Western blot analysis for α-SMA in livers from Vehicle or Terutroban-treated BDL 
rats. Bottom: Densitometry quantification in arbitrary units (AU), normalized to GAPDH, showed no 
differences between both groups. (n=14 per group).  
(D) TGF-β mRNA expression levels in livers from BDL-cirrhotic rats treated with Terutroban or Vehicle 
showed no differences between both groups. (n=14 per group). Data are presented as mean ± SEM.  
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CCl4           
   Vehicle (n=8)  Terutroban (n=10)  pvalue  
     AST (U/L)  276 ± 170  206 ± 117  ns  
     ALT (U/L)  106 ± 57  105 ± 43  ns  
     Bilirubin (mg/dL)  0.3 ± 0.3  0.2 ± 0.4  ns  
     Albumin (g/L)  22.8 ± 4  27.6 ± 2  < 0,05  
     Body weight (g)  361 ± 29  356 ± 17  ns  
     Liver weight (g)  8.6 ± 2,4  9.4 ± 1  ns  
     Spleen weight (g)  0.93 ± 0.2  0,92 ± 0.1  ns  
 
BDL           
   Vehicle (n=16)  Terutroban (n=14)  pvalue  
     AST (U/L)  480 ± 181  667 ± 382  ns  
     ALT (U/L)  95 ± 37  112 ± 46  ns  
     Bilirubin (mg/dL)  7.4 ± 1.2  6.4 ± 1.8  ns  
     Albumin (g/L)  23 ± 4  20 ± 4  ns  
     Body weight (g)  324 ± 26  315 ± 33  ns  
     Liver weight (g)  18.1 ± 3.9  17.1 ± 4.8  ns  
     Spleen weight (g)  1.7 ± 0.3  1.6 ± 0.4  ns  
Data are presented as mean ± SD. 
AST, aspartate aminotransferase; ALT, alanine aminotransferase. 
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